Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
84 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Diphtheria - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Diphtheria - Pipeline Review, H2 2014', provides an overview of the Diphtheria's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Diphtheria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diphtheria and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Diphtheria - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diphtheria and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diphtheria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diphtheria pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diphtheria - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diphtheria pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Diphtheria Overview 9 Therapeutics Development 10 Pipeline Products for Diphtheria - Overview 10 Pipeline Products for Diphtheria - Comparative Analysis 11 Diphtheria - Therapeutics under Development by Companies 12 Diphtheria - Therapeutics under Investigation by Universities/Institutes 14 Diphtheria - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Diphtheria - Products under Development by Companies 19 Diphtheria - Products under Investigation by Universities/Institutes 21 Diphtheria - Companies Involved in Therapeutics Development 22 Beijing Minhai Biotechnology Co., Ltd 22 Biological E. Limited 23 Daiichi Sankyo Company, Limited 24 GlaxoSmithKline plc 25 Green Cross Corporation 26 Indian Immunologicals Limited 27 LG Life Sciences, Ltd. 28 Novartis AG 29 Panacea Biotec Limited 30 Prometheon Pharma, LLC 31 Sanofi 32 Sanofi Pasteur SA 33 Serum Institute of India Limited 34 Sinovac Biotech Ltd. 35 Takeda Pharmaceutical Company Limited 36 Zydus Cadila Healthcare Limited 37 Diphtheria - Therapeutics Assessment 38 Assessment by Monotherapy Products 38 Assessment by Combination Products 39 Assessment by Target 40 Assessment by Route of Administration 42 Assessment by Molecule Type 44 Drug Profiles 46 (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis + haemophilus influenza [serogroup B]) vaccine - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 diphtheria + pertussis + tetanus vaccine - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 diphtheria + pertussis + tetanus vaccine - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [type B] + polio (pentavalent) vaccine - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [type B] + polio (hexavalent) vaccine - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 diphtheria + tetanus+ pertussis vaccine - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 diphtheria vaccine - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 diphtheria vaccine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 diptheria + tetanus + pertussis (whole-cell) vaccine - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 diptheria + tetanus vaccine - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 DPT-H-HiB Vaccine - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 DTaP Vaccine - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 GC-1107 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 GC-3111A - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 GSK-217744 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Quadracel - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 TAK-361S - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 tetanus + diphtheria + pertussis (acellular) vaccine - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 VN-0103 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Diphtheria - Recent Pipeline Updates 73 Diphtheria - Dormant Projects 75 Diphtheria - Product Development Milestones 76 Featured News & Press Releases 76 Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine 76 Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel� Tdap Vaccine to Include Persons 10 Years of Age 77 Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima 77 Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine 78 Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 79 Jun 22, 2012: Sanofi Pasteur's Hexaxim Receives Positive Opinion From European Medicines Agency 79 Nov 16, 2011: Quadrivalent Vaccine TAK-361S Enters Into Phase II Clinical Trials In Japan 80 Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis 81 Jun 13, 2005: U.S. FDA Licenses sanofi pasteur's ADACEL Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis 81 Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine 82 Appendix 83 Methodology 83 Coverage 83 Secondary Research 83 Primary Research 83 Expert Panel Validation 83 Contact Us 84 Disclaimer 84
List of Tables Number of Products under Development for Diphtheria, H2 2014 10 Number of Products under Development for Diphtheria - Comparative Analysis, H2 2014 11 Number of Products under Development by Companies, H2 2014 13 Number of Products under Investigation by Universities/Institutes, H2 2014 14 Comparative Analysis by Late Stage Development, H2 2014 15 Comparative Analysis by Clinical Stage Development, H2 2014 16 Comparative Analysis by Early Stage Development, H2 2014 17 Comparative Analysis by Unknown Stage Development, H2 2014 18 Products under Development by Companies, H2 2014 19 Products under Development by Companies, H2 2014 (Contd..1) 20 Products under Investigation by Universities/Institutes, H2 2014 21 Diphtheria - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2014 22 Diphtheria - Pipeline by Biological E. Limited, H2 2014 23 Diphtheria - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 24 Diphtheria - Pipeline by GlaxoSmithKline plc, H2 2014 25 Diphtheria - Pipeline by Green Cross Corporation, H2 2014 26 Diphtheria - Pipeline by Indian Immunologicals Limited, H2 2014 27 Diphtheria - Pipeline by LG Life Sciences, Ltd., H2 2014 28 Diphtheria - Pipeline by Novartis AG, H2 2014 29 Diphtheria - Pipeline by Panacea Biotec Limited, H2 2014 30 Diphtheria - Pipeline by Prometheon Pharma, LLC, H2 2014 31 Diphtheria - Pipeline by Sanofi, H2 2014 32 Diphtheria - Pipeline by Sanofi Pasteur SA, H2 2014 33 Diphtheria - Pipeline by Serum Institute of India Limited, H2 2014 34 Diphtheria - Pipeline by Sinovac Biotech Ltd., H2 2014 35 Diphtheria - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 36 Diphtheria - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 37 Assessment by Monotherapy Products, H2 2014 38 Assessment by Combination Products, H2 2014 39 Number of Products by Stage and Target, H2 2014 41 Number of Products by Stage and Route of Administration, H2 2014 43 Number of Products by Stage and Molecule Type, H2 2014 45 Diphtheria Therapeutics - Recent Pipeline Updates, H2 2014 73 Diphtheria - Dormant Projects, H2 2014 75
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.